Navigation Links
New genetic research into nicotine addiction shows promise for personalized treatment

Whether a smoking-cessation drug will enable you to quit smoking may depend on your genes, according to new genotyping research from the Centre for Addiction and Mental Health (CAMH). The study, published in the September issue of the journal Biological Psychiatry, found that the enzyme known to metabolize both the smoking cessation drug bupropion and nicotine is highly genetically variable in all ethnicities and influences smoking cessation. This finding is a step toward being able to tailor smoking cessation treatment to individuals based on their unique genetic make-up.

This first study identifies a very common genetic variant (present in anywhere from 25 to 50 percent of world populations) that appears to affect the outcome of smoking cessation treatment, said Rachel Tyndale, Section Head of Pharmacogenetics at CAMH and lead researcher on the study, adding that the results would have to be replicated.

Tyndale and colleagues performed genotyping on smokers for CYP2B6, a gene known to be highly variable and whose enzyme metabolizes bupropion, nicotine and serotonin. Participants were then provided with either placebo or bupropion treatment for ten weeks and followed up for 6 months.

The research project, supported by the Canadian Institutes of Health Research and the National Institute of Health, found that 45% of individuals with a specific variant of the gene benefited from bupropion treatment and maintained abstinence longer while doing poorly on placebo, with a 32.5% abstinent rate vs. 14.3%, respectively. In contrast, the 55% with a different variant of the gene (wild type variant) had good abstinences rates on placebo and gained no additional benefit from Bupropion, suggesting no benefit from treating these individuals with Bupropion. Of note, this group was able to quit smoking very well in the absence of an active drug (on placebo).

What percentage of people fall into the group that appeared to benefit" Previous studies have shown that 45%, 50% and 25% of White, African and Asian North Americans have the former specific variant form of the CYP2B6 gene.

The current study looked only at people of European ancestry, says Dr. Tyndale, but she and her colleagues have begun a similar study in African American smokers. They hypothesize that the variant form of the CYP2B6 gene will influence the effectiveness of bupropion treatment and ability to quit smoking in the same way in African Americans as in those of European descent.


Contact: Michael Torres
Centre for Addiction and Mental Health

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Mouse brain tumors mimic those in human genetic disorder
5. Genetically modified natural killer immune cells attack, kill leukemia cells
6. Scientists identify genetic pathways essential to RNA interference
7. Ants Genetic Engineering Leads To Species Interdependency
8. Researchers trace evolution to relatively simple genetic changes
9. Genetic Variation Visualization - From EMBL
10. Genetically modified rice in China benefits farmers health, study finds
11. Key mechanism in genetic inheritance during cell division identified
Post Your Comments:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
Breaking Biology Technology: